Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference
Data from DELIVER and ACHIEVE Clinicals Trial to be Presented -- Presentation on ACHIEVE Trial in DM1 and Company Symposium to Feature Data on ...
Exxon consolidates Proxxima operations in Baytown, continues growth
Exxon spent the past year moving a lab's operations from California to Baytown and plans to increase its number of employees ...
DMD market expected to grow to $5.2bn in the 7MM by 2033
The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, ...
Managed Healthcare Executive2d
Entrada Therapeutics On Track For New DMD Study in the U.K.
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
Cfr.org2d
CFIUS Reviews Should Be Subject to Judicial Scrutiny
Biden’s decision underscored two key challenges with the current CFIUS process: the absence of a clear tiered framework to ...
Is Exxon Mobil (XOM) the Best Widow and Orphan Stock to Invest In?
We recently published a list of 10 Best Widow and Orphan Stocks To Invest In. In this article, we are going to take a look at ...
Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting
The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclastinib for at least 48 weeks to highlight the symptomatic benefits of long-term use.
Johnson & Johnson (JNJ) Among the Best Stocks to Buy for Financial Stability
We recently published a list of 10 Best Stocks To Buy For Financial Stability. In this article, we are going to take a look ...
News Medical on MSN6d
Understanding the role of alternative splicing in cardiovascular diseases
Announcing a new article publication for Cardiovascular Innovations and Applications journal. Alternative splicing (AS), a ...